EZH2 and lymphoma: Phase II trials with the drug Tazemetostat have demonstrated favorable results in lymphoma patients carrying EZH2 mutations, achieving an impressive 69% objective response rate, while those with wild‐type EZH2 just saw 35% of response rate [27].